Tree Line Advisors (Hong Kong) Ltd. Zai Lab LTD Transaction History

Tree Line Advisors (Hong Kong) Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 29, 2022	SELL	$27.77 - $64.4 $3.89 Million - $9.02 Million	-140,000 Reduced 23.33%	460,000 $20.2 Million
Q3 2021 Nov 15, 2021	SELL	$105.0 - $178.37 $8.4 Million - $14.3 Million	-80,000 Reduced 11.76%	600,000 $63.2 Million
Q1 2021 May 17, 2021	SELL	$126.27 - $191.71 $12.9 Million - $19.6 Million	-102,000 Reduced 13.04%	680,000 $90.7 Million
Q4 2020 Feb 12, 2021	SELL	$81.94 - $135.34 $7.62 Million - $12.6 Million	-93,000 Reduced 10.63%	782,000 $106 Million
Q2 2019 Aug 02, 2019	BUY	$25.73 - $35.79 $9.01 Million - $12.5 Million	350,000 Added 66.67%	875,000 $30.5 Million
Q1 2019 Apr 18, 2019	BUY	$21.71 - $31.54 $2.28 Million - $3.31 Million	105,000 Added 25.0%	525,000 $15.5 Million
Q4 2018 Feb 06, 2019	BUY	$14.95 - $24.72 $6.28 Million - $10.4 Million	420,000 New	420,000 $9.75 Million

121

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.95B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Tree Line Advisors (Hong Kong) Ltd., based on Form 13F filings with the SEC.

Stay updated on Tree Line Advisors (Hong Kong) Ltd. with notifications on news.